School of Medicine
Showing 61-80 of 125 Results
-
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
David Liang, MD, PhD
Professor of Medicine (Cardiovascular) at the Stanford University Medical Center, Emeritus
BioStanford researchers are creating a micro-device that physicians could guide through the body to help diagnose and treat clogged arteries and other diseases. Tethered to the outside world by a thin wire, a tiny machine creeps through blood vessels, searching out deadly plaques and obliterating them with a zap of a laser. While a laser will come later, for now David Liang, MD, PhD, is focusing on a tiny eye that could give physicians an unprecedented view into blood vessels.
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
Malene Lindholm
Instructor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsInterested in the genetics of human performance and the multi-omic response to exercise and training for optimizing human health.
-
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained se ttings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; chair of the board at EPPIC Global Network; chair of Faculty Alumni Network at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Sanjiv Narayan
Professor of Medicine (Cardiovascular Medicine)
On Partial Leave from 09/05/2023 To 06/30/2024Current Research and Scholarly InterestsDr. Narayan directs the Computational Arrhythmia Research Laboratory, whose goal is to define the mechanisms underlying complex human heart rhythm disorders, to develop bioengineering-focused solutions to improve therapy that will be tested in clinical trials. The laboratory has been funded continuously since 2001 by the National Institutes of Health, AHA and ACC, and interlinks a disease-focused group of clinicians, computational physicists, bioengineers and trialists.
-
Koen Nieman
Professor of Medicine (Cardiovascular Medicine) and of Radiology (CV Imaging)
Current Research and Scholarly InterestsDr Nieman investigates advanced cardiac imaging techniques. Current projects focus on the development of functional CT application for hemodynamic interpretation of coronary artery disease, and the clinical validation of cardiac CT in the management of patients with ischemic heart disease.
-
Joyce Njoroge, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Njoroge is a board-certified physician and fellowship-trained cardiologist with the Advanced Heart Failure Program at Stanford Health Care. She is also a clinical assistant professor of medicine in the Division of Cardiovascular Medicine.
Dr. Njoroge has extensive clinical experience diagnosing and treating cardiovascular complications that develop during pregnancy or postpartum. She currently provides care at the Stanford Health Care Heart and Vascular Clinic with a particular focus on patients with a history of pregnancy-associated heart failure and cardiomyopathy.
Dr. Njoroge’s research efforts involve identifying inherited genetic changes and biological markers that could help improve screening and care for pregnant women in higher risk populations. This includes determining the causes of disproportionately high incidences of heart-related complications and deaths experienced by Black women during and after pregnancy. Dr. Njoroge is also currently recruiting patients for a large-scale, multicenter clinical trial evaluating a drug to treat cardiovascular complications during pregnancy.
Dr. Njoroge has published her work in numerous prestigious peer-reviewed journals, including Circulation Research and the Journal of Cardiac Failure. She also co-authored a chapter on cardiovascular disease in pregnancy in the most recent edition of the book Current Diagnosis and Treatment: Cardiology.
Dr. Njoroge is a member of the Association of Black Cardiologists, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America. -
Latha Palaniappan, MD, MS
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Palaniappan has published over 200 peer reviewed manuscripts, abstracts, and book chapters over the last 20 years in the areas of chronic disease prevention and treatment in diverse populations. She has expertise in epidemiological research using big data, use of electronic health records for research, and clinical trials.
-
Victoria Parikh
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Parikh is a clinician scientist who cares for patients with and studies inherited (genetic) cardiovascular disease. She is the director of the Stanford Center for Inherited Cardiovascular Disease (SCICD) which is one of the largest of its kind in the country. SCICD integrates clinical and basic science with the expert care of patients with genetic cardiovascular conditions (e.g., cardiomyopathies, arrhythmias and vascular diseases). It provides cutting edge care for thousands of patients and families across the lifespan and integrates medical, surgical and genetics care. Our team includes physicians, nurses, advanced practice providers, genetic counselors, exercise physiologists and scientists.
Dr. Parikh's own clinical practice and laboratory are focused on the genetics of cardiomyopathies and their associated arrhythmogenic substrates. She completed clinical cardiology fellowship at Stanford School of Medicine and her medical residency at the University of California, San Francisco. Funded by multiple research grants from the NIH, her lab seeks to identify novel mechanisms and therapeutic technologies for genetic cardiomyopathy as well as better understand the natural histories of patients affected by these diseases. -
Marco Perez
Associate Professor of Medicine (Cardiovascular Medicine)
BioDr. Marco Perez's research goal is to better understand the fundamental causes of cardiovascular disease through the study of genetics and epidemiology. His group studies the genetic variations and environmental exposures that are associated with conditions such as atrial fibrillation and heart failure. He has led the studies of atrial fibrillation in Women's Health Initiative, one of the largest nation-wide population-based cohorts. He is currently conducting a large study monitoring for silent or asymptomatic atrial fibrillation in women from the WHI randomized to exercise intervention, and was co-PI of the Apple Heart Study, a clinical trial that validated the ability of a smartwatch to detect atrial fibrillation. He is now PI of the Clinical Coordinating Center at Stanford for the REACT-AF which is a clinical trial to evaluate efficacy and safety of a "pill-in-the pocket" approach to anticoagulation for AF using a smartwatch. He is interested in understanding the paradox that atrial fibrillation is less common in African Americans and Hispanics, despite a greater burden of risk factors such as hypertension. As director of the Stanford Inherited Arrhythmia Clinic, he evaluates families with rare inherited arrhythmias associated with sudden death such as Long QT and Brugada Syndromes and explores their links with novel genes. He also studies the genetic causes of very early onset atrial fibrillation. He also studies how best to use the electrocardiogram and imaging modalities using Machine Learning techniques to identify patients at risk for cardiovascular disease. Dr. Perez receives funding from the NIH/NHLBI, Apple Inc., Janssen and the Colson Foundation.
